During the past decade, University of Kansas Medical Center, Department of Neurology conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 4 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Kansas Medical Center, Department of Neurology" #1 sponsor was "Genzyme, a Sanofi Company" with 2 trials, followed by "OPKO Health, Inc." with 2 trials sponsored, "Sunovion" with 2 trials sponsored, "Biogen" with 1 trials sponsored and "Cephalon" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Kansas Medical Center, Department of Neurology" #1 collaborator was "Bayer" with 2 trials as a collaborator, "Elan Pharmaceuticals" with 1 trials as a collaborator, "H. Lundbeck A/S" with 1 trials as a collaborator, "Office of Rare Diseases (ORD)" with 1 trials as a collaborator and "Rare Diseases Clinical Research Network" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "University of Kansas Medical Center, Department of Neurology" are "Multiple Sclerosis, Relapsing-Remitting" (3 trials), "Parkinson Disease" (2 trials), "ALS" (1 trials), "Alzheimer Disease" (1 trials) and "Alzheimer's Disease" (1 trials). Many other conditions were trialed in "University of Kansas Medical Center, Department of Neurology" in a lesser frequency.

Most popular intervention types in "University of Kansas Medical Center, Department of Neurology" are "Drug" (8 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "APL-130277" (2 trials), "Placebo" (2 trials), "Alemtuzumab 12 mg" (1 trials), "Alemtuzumab 24 mg" (1 trials) and "C105" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Kansas Medical Center, Department of Neurology" are 11 trials for "All" genders.

Currently, there are NaN active trials in "University of Kansas Medical Center, Department of Neurology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in University of Kansas Medical Center, Department of Neurology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in University of Kansas Medical Center, Department of Neurology, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".